# A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

> **NCT05653869** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Applied Pharmaceutical Science, Inc.** · enrollment: 108 (actual)

## Conditions studied

- RET-altered Solid Tumors

## Interventions

- **DRUG:** APS03118

## Key facts

- **NCT ID:** NCT05653869
- **Lead sponsor:** Applied Pharmaceutical Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-06
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653869, "A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05653869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*